Pre-Open Stock Movers: View, Inc. (VIEW) 56% LOWER; delays its 10-Q. Unity Software Inc. (U) 33% LOWER; reported Q1 EPS of ($0.08), $0.01 better than the analyst estimate of...
By Oliver Gray Investing.com - U.S. stock futures were little changed during Tuesday’s evening deals after major benchmark averages finished the regular session lower amid...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
As the world eagerly awaits results for the U.S. Presidential election, there's yet another highly anticipated event: a breakthrough in the coronavirus vaccine. Positive news about...
When August ended, stocks looked poised to move higher. The Federal Reserve had promised to keep interest rates at record low levels, effectively telling investors and anyone else...
Inovio Pharmaceuticals, Inc. (INOVIO) is a biotechnology company. The Company is focused on bringing to market designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus (HPV). Its DNA medicines pipeline consists of three types of product candidates, namely prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies (dMAbs and dBTAs), which utilizes the two components of INOVIO's integrated platform, SynCon and CELLECTRA. The Company's SynCon technology creates optimized plasmids. INOVIO's CELLECTRA smart delivery devices facilitate uptake of its DNA medicines into the cell. Its SynCon DNA medicines are designed to generate antigen-specific antibody and T cell responses.
|Average||5.000 (+184.09% Upside)|
|No. of Analysts||6|